This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene: Abraxane Boosts Pancreatic Cancer Survival

Updated with new information.

SUMMIT, NJ ( TheStreet) -- The cancer drug Abraxane prolonged the survival of patients with advanced pancreatic cancer in a closely watched phase III study, Celgene (CELG - Get Report) said Friday night.

A competing pancreatic cancer drug from Clovis Oncology (CLVS)failed to prolong survival in its phase III study, the company announced early Monday.

Celgene plans to seek regulatory approval to expand Abraxane's label to include treatment for pancreatic cancer based on the positive study results. In a best case, pancreatic cancer could add another $1 billion in Abraxane sales.

Abraxane sales totaled $320 million in the first nine months of the year, mainly from use in advanced breast cancer. In October, the FDA approved Abraxane for use in non-small cell lung cancer and Celgene reported positive results from a phase III study in melanoma.

In this latest study, 861 treatment-naive pancreatic cancer patients were randomized to treatment with Abraxane plus the chemotherapy gemcitabine or gemcitabine alone. The combination of Abraxane/gemcitabine demonstrated a statistically significant improvement in overall survival, the study's primary endpoint. Abraxane was well tolerated.

Further details from the study will be presented at a cancer research meeting in January, Celgene said.

Celgene designed the pancreatic cancer study to show an approximate two-month survival advantage for Abraxane plus gemcitabine over gemcitabine alone. Historically, patients treated with gemcitabine alone live about six months.

Investors are likely to view a survival benefit of 8 months for Abraxane/gemcitabine compared to 6 months for gemcitabine alone as a very positive result.

Analyst models, on average, are forecasting $733 million in Abraxane sales in 2015, according to ISI Group analyst Mark Schoenebaum. That estimate will rise significantly if the Abraxane pancreatic cancer survival benefit is robust.

An estimated 44,000 people are diagnosed with pancreatic cancer in the U.S. each year and 37,000 die, according to U.S. health statistics.

Celgene shares closed Friday $71.50 ahead of the Abraxane data announcement. The stock rose 6% to $75.57 in after-hours trading.

The Celgene CVR jumped 80% to $5.60 in Friday's after-hours session. Celgene created the contingent value right linked to Abraxane when it acquired the drug's original owner Abraxis BioScience in 2010.

In September, hedge fund manager and TheStreet contributor Jim Silverman recommended buying the Celgene CVR based on his belief that the Abraxane pancreatic cancer trial would be successful.

"What I like about the Celgene CVR is the potential for a nearly $7.50-per-share payout should a phase III study of Abraxane in pancreatic cancer succeed," Silverman wrote. At that time, the Celgene CVR was worth $2.50 per share.

TheStreet contributor Nate Sadeghi also predicting a win for Abraxane in pancreatic cancer in an October column. Abraxane generated a lot of positive buzz at a European cancer research meeting in early October.

Friday's Abraxane data could impact Threshold Therapeutics (THLD - Get Report) and partner Merck KGaA, which are planning to soon begin a phase III study of their drug TH-302.

Clovis Oncology said Monday experimental drug CO-101 failed to prolong survival compared to treatment with gemcitabine. Based on the negative result, Clovis is disontinuing all development of the drug.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELGZ $1.12 -1.34%
CELG $100.90 -2.25%
CLVS $13.19 -5.45%
THLD $0.41 -2.36%
AAPL $94.19 -1.04%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs